
While the challenges of quality and speed of design, data and reporting for regulatory submissions continue for the biopharmaceutical industry, the paradigm of value-based healthcare has gained prominence across all healthcare stakeholders. How to estimate value of the intervention for optimal pricing and access is the key question to answer. There’s uncertainty around how the risk benefit profile of a health intervention translates from clinical development to the real world. Real world data analytics allows modelling of this uncertainty and enables decisions about risk sharing and risk rationalization across stakeholders.
Find Us on Social Platforms